Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC

Phil A J Crosbie, Rajesh Shah, Piotr Krysiak, Cong Zhou, Karen Morris, Jonathan Tugwood, Richard Booton, Fiona Blackhall, Caroline Dive, Phil A J Crosbie, Rajesh Shah, Piotr Krysiak, Cong Zhou, Karen Morris, Jonathan Tugwood, Richard Booton, Fiona Blackhall, Caroline Dive

Abstract

Tumor recurrence after surgical resection of NSCLC obstructs long-term disease-free survival in approximately 50% of cases. Our data suggest that combining circulating tumor cell enumeration (as single cells or clusters) in tumor-draining pulmonary vein and peripheral blood (assessed by CellSearch) at the time of NSCLC surgery better identifies those patients at higher risk for lung cancer recurrence than does peripheral circulating tumor cell number alone.

Keywords: Circulating tumor cells; Early stage; NSCLC; Recurrence; Surgery.

Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Figures

Figure 1
Figure 1
Survival in patients after curative-intent surgical resection of NSCLC. (A) Disease-free survival (DFS) and (B) 3-year overall survival (OS) according to pulmonary vein circulating tumor cell (CTC) status. (C) DFS and (D) 3-year OS according to peripheral vein CTC detection. (E) DFS and (F) 3-year OS stratified according to high- and low-risk CTC groups. CMT, circulating tumor microemboli.

References

    1. Baccelli I., Schneeweiss A., Riethdorf S. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013;31:539–544.
    1. Hodgkinson C.L., Morrow C.J., Li Y. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med. 2014;20:897–903.
    1. Hofman V., Ilie M.I., Long E. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch assay and the isolation by size of epithelial tumor cell method. Int J Cancer. 2011;129:1651–1660.
    1. Krebs M.G., Sloane R., Priest L. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011;29:1556–1563.
    1. Hashimoto M., Tanaka F., Yoneda K. Significant increase in circulating tumour cells in pulmonary venous blood during surgical manipulation in patients with primary lung cancer. Interact Cardiovasc Thorac Surg. 2014;18:775–783.
    1. Allard W.J., Matera J., Miller M.C. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–6904.
    1. Riethdorf S., Fritsche H., Muller V. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007;13:920–928.
    1. Hou J.M., Krebs M.G., Lancashire L. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 2012;30:525–532.
    1. Krebs M.G., Metcalf R.L., Carter L., Brady G., Blackhall F.H., Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol. 2014;11:129–144.
    1. Fidler I.J. Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2′-deoxyuridine. J Natl Cancer Inst. 1970;45:773–782.
    1. Liotta L.A., Saidel M.G., Kleinerman J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res. 1976;36:889–894.
    1. Cohen S.J., Punt C.J., Iannotti N. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20:1223–1229.
    1. Cristofanilli M., Budd G.T., Ellis M.J. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–791.
    1. de Bono J.S., Scher H.I., Montgomery R.B. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302–6309.
    1. Jamal-Hanjani M., Hackshaw A., Ngai Y. Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS Biol. 2014;12:e1001906.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner